PKD2 and autosomal dominant polycystic kidney disease: While previous drug screens have identified ADPKD drug repurposing candidates using pkd2 mutant tail phenotypes in zebrafish (Cao et al. 2009; Metzner et al. 2020) and in Pkd1 knock-out mice across disease stages (Malas et al. 2020), our study is the first to our knowledge to apply signature reversion to the problem of identifying drug repurposing candidates for ADPKD (Zhou and Torres 2023).